Form 8-K - Current report:
SEC Accession No. 0001144204-16-090941
Filing Date
2016-03-29
Accepted
2016-03-29 16:22:59
Documents
5
Period of Report
2016-03-23
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K v435580_8k.htm 8-K 26731
2 EXHIBIT 10.2 v435580_ex10-2.htm EX-10.2 37213
3 EXHIBIT 10.3 v435580_ex10-3.htm EX-10.3 38466
4 EXHIBIT 99.1 v435580_ex99-1.htm EX-99.1 90347
5 GRAPHIC image_002.jpg GRAPHIC 23246
  Complete submission text file 0001144204-16-090941.txt   226315
Mailing Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017
Business Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 161535637
SIC: 2835 In Vitro & In Vivo Diagnostic Substances